### ü´Å Pulmonary Medicine: Malignant Pleural Effusion Management

#### ‚úÖ True Statements
1. A **malignant pleural effusion** signifies **advanced disease** and an **overall poor prognosis**.  
2. The **goal of management** for malignant pleural effusion is **symptom relief**.  
3. **Indwelling pleural catheters** with intermittent drainage provide **significant symptom relief** in malignant pleural effusion.  
4. Placement of an **indwelling pleural catheter** results in a **50% rate of spontaneous pleurodesis** within **6‚Äì8 weeks**.  
5. **Chemical pleurodesis** refers to **obliteration of the pleural space** with a **sclerosing agent** (e.g., talc) introduced via **thoracostomy tube** or **thoracoscopy**.  
6. **Talc pleurodesis** has a **success rate of 60%‚Äì90%**.  
7. **Chemical pleurodesis** is **less effective** in malignant pleural effusion when there is **incomplete lung expansion** after thoracentesis.  
8. The **success of chemical pleurodesis** depends on **full lung expansion** and **apposition of pleural surfaces**.  
9. **Repeat thoracentesis** may be appropriate if the **rate of fluid reaccumulation is slow** (greater than 1 month).  

#### üí¨ Extra
1. Median survival after diagnosis of malignant pleural effusion is approximately **4‚Äì7 months**.  
3. Indwelling pleural catheters can be managed **outpatient** with intermittent drainage.  
5. **Talc poudrage** (thoracoscopic insufflation) and **talc slurry** (tube instillation) are both methods of pleurodesis.  
9. Repeat thoracentesis is more suitable in patients with **poor prognosis (<3 months)**.  

#### üè∑Ô∏è Tags
#PulmonaryMedicine #PleuralDisease #MalignantPleuralEffusion #IndwellingCatheter #Pleurodesis #AmbulatoryCare  

#### üìö Reference
Shafiq M, Feller-Kopman D. Management of malignant pleural effusions. *Clin Chest Med*. 2020;41:259-67. PMID: 32402361 doi:10.1016/j.ccm.2020.02.009  

#### üÜî Question ID
PMMCQ24029  

#### üïí Last Updated
February 2025  

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Pleural Disease, Pleural Effusion, Management of Pleural Effusion, Malignant Pleural Effusion  

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. The **median prognosis** after diagnosis of malignant pleural effusion is **4‚Äì7 months**.  
2. **Treatment decisions** for malignant pleural effusion should be based on **symptoms**, **prognosis**, **degree of anticipated lung reexpansion**, and **patient performance status**.  
3. **Repeat therapeutic thoracentesis** is appropriate for malignant pleural effusion in patients with **poor prognosis (<3 months)** and **slow reaccumulation of fluid**.  
4. Patients with **rapid reaccumulation of fluid** and **dyspnea** from malignant pleural effusion should be offered **more definitive management** (e.g., catheter or pleurodesis).  
5. **Indwelling pleural catheters** provide **substantial symptom relief** in malignant pleural effusion.  
6. Approximately **50% of patients** with malignant pleural effusion achieve **spontaneous pleurodesis within 6‚Äì8 weeks** of indwelling catheter placement.  
7. **Talc pleurodesis** has a **success rate of 60%‚Äì90%**, depending on the degree of **lung reexpansion**.  
8. **Pleurodesis** is **less effective** in malignant pleural effusion with **incomplete lung reexpansion** after thoracentesis.  

#### üí¨ Extra
2. Management choices are individualized and incorporate **patient goals of care**.  
3. Repeat thoracentesis is often chosen when **life expectancy is short** and **invasive interventions are not beneficial**.  
7. **Thoracoscopic talc poudrage** generally has higher efficacy than **tube talc slurry**, though both are widely used.  

#### üè∑Ô∏è Tags
#PulmonaryMedicine #PleuralEffusion #Malignancy #Catheter #TalcPleurodesis  
